Skip to main content
. 2009 May 14;10(5):2136–2145. doi: 10.3390/ijms10052136

Figure 3.

Figure 3.

Cytotoxicity of RADA16-I against human leukemia cells and HUVECs by MTT proliferation assay. (A) MTT assay showed that RADA16-I had no cytotoxicity for both K562 and Jurkat cells. After treated with RADA16-I solution at the maximal concentration (2mM), the relative viabilities of K562 and Jurkat cells were 101.66 ± 4.25% and 97.44 ± 5.66%, respectively. RADA16-I solutions at lower concentrations even enhanced the proliferation of cells. (B) MTT assay displayed that RADA16-I had almost no cytotoxicity against HUVECs even at 80 μM peptide concentration (92.90 ± 3.54% viability). Data shown are Means ± SD.